Age-related features of lung cancer treatment using reprogrammed CD8 positive T cells in mice subjected to injection of Lewis lung carcinoma cells.

IF 2.3 3区医学 Q3 ONCOLOGY

Thoracic Cancer Pub Date : 2024-08-22 DOI:10.1111/1759-7714.15426

Evgenii Skurikhin, Mariia Zhukova, Natalia Ermakova, Edgar Pan, Darius Widera, Lubov Sandrikina, Lena Kogai, Nikolai Kushlinskii, Aslan Kubatiev, Sergey Morozov, Alexander Dygai

{"title":"Age-related features of lung cancer treatment using reprogrammed CD8 positive T cells in mice subjected to injection of Lewis lung carcinoma cells.","authors":"Evgenii Skurikhin, Mariia Zhukova, Natalia Ermakova, Edgar Pan, Darius Widera, Lubov Sandrikina, Lena Kogai, Nikolai Kushlinskii, Aslan Kubatiev, Sergey Morozov, Alexander Dygai","doi":"10.1111/1759-7714.15426","DOIUrl":null,"url":null,"abstract":"Background: Awareness of age-related features of carcinogenesis and the importance of cellular immunity is crucial for developing effective antitumor therapies for specific patient groups.Methods: In this study, we examined different populations of cancer stem cells (CSCs) and circulating tumor cells (CTCs) in \"young\" (8-10 weeks) and \"aged\" (80-82 weeks) C57BL/6 male mice. We used an orthotopic model of Lewis lung carcinoma (LLC) to evaluate the effectiveness of cell therapy targeting lung cancer through reprogrammed CD8-positive T cells (rCD8+ T cells) in mice from two different ages.Results: The findings revealed that tumor progression with age is primarily caused by impaired recruitment of T cells to the lungs. Additionally, a lower number of CTCs and CSCs were observed in younger mice compared to the older mice. The antitumor effect of rCD8+ T cells in aged mice was found to be inferior to that in young mice, which can be attributed to the reduced impact of therapy on specific CSCs populations.Conclusions: These results offer new insights into the treatment of lung cancer using rCD8+ T cells. Considering the age-related characteristics influencing disease progression, this therapy has the potential to significantly enhance the effectiveness of treatment methods.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thoracic Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1759-7714.15426","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Awareness of age-related features of carcinogenesis and the importance of cellular immunity is crucial for developing effective antitumor therapies for specific patient groups.

Methods: In this study, we examined different populations of cancer stem cells (CSCs) and circulating tumor cells (CTCs) in "young" (8-10 weeks) and "aged" (80-82 weeks) C57BL/6 male mice. We used an orthotopic model of Lewis lung carcinoma (LLC) to evaluate the effectiveness of cell therapy targeting lung cancer through reprogrammed CD8-positive T cells (rCD8+ T cells) in mice from two different ages.

Results: The findings revealed that tumor progression with age is primarily caused by impaired recruitment of T cells to the lungs. Additionally, a lower number of CTCs and CSCs were observed in younger mice compared to the older mice. The antitumor effect of rCD8+ T cells in aged mice was found to be inferior to that in young mice, which can be attributed to the reduced impact of therapy on specific CSCs populations.

Conclusions: These results offer new insights into the treatment of lung cancer using rCD8+ T cells. Considering the age-related characteristics influencing disease progression, this therapy has the potential to significantly enhance the effectiveness of treatment methods.

查看原文本刊更多论文

使用重编程 CD8 阳性 T 细胞治疗注射 Lewis 肺癌细胞的小鼠肺癌的年龄相关特征。

背景：了解与年龄相关的癌变特征以及细胞免疫的重要性，对于开发针对特定患者群体的有效抗肿瘤疗法至关重要：在这项研究中，我们检测了 "年轻"（8-10周）和 "衰老"（80-82周）C57BL/6雄性小鼠体内癌症干细胞（CSCs）和循环肿瘤细胞（CTCs）的不同群体。我们利用路易斯肺癌（LLC）的正位模型，评估了通过重编程 CD8 阳性 T 细胞（rCD8+ T 细胞）对两种不同年龄小鼠肺癌进行细胞治疗的效果：结果：研究结果表明，随着年龄的增长，肿瘤进展的主要原因是T细胞招募到肺部的能力受损。此外，与年龄较大的小鼠相比，年龄较小的小鼠体内观察到的 CTC 和 CSC 数量较少。研究发现，rCD8+ T细胞对老年小鼠的抗肿瘤效果不如年轻小鼠，这可能是由于治疗对特定CSCs群体的影响减弱所致：这些结果为利用 rCD8+ T 细胞治疗肺癌提供了新的见解。考虑到影响疾病进展的年龄相关特征，这种疗法有可能显著提高治疗方法的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Thoracic Cancer ONCOLOGY-RESPIRATORY SYSTEM

CiteScore

5.20

自引率

3.40%

发文量

439

审稿时长

2 months

期刊介绍： Thoracic Cancer aims to facilitate international collaboration and exchange of comprehensive and cutting-edge information on basic, translational, and applied clinical research in lung cancer, esophageal cancer, mediastinal cancer, breast cancer and other thoracic malignancies. Prevention, treatment and research relevant to Asia-Pacific is a focus area, but submissions from all regions are welcomed. The editors encourage contributions relevant to prevention, general thoracic surgery, medical oncology, radiology, radiation medicine, pathology, basic cancer research, as well as epidemiological and translational studies in thoracic cancer. Thoracic Cancer is the official publication of the Chinese Society of Lung Cancer, International Chinese Society of Thoracic Surgery and is endorsed by the Korean Association for the Study of Lung Cancer and the Hong Kong Cancer Therapy Society. The Journal publishes a range of article types including: Editorials, Invited Reviews, Mini Reviews, Original Articles, Clinical Guidelines, Technological Notes, Imaging in thoracic cancer, Meeting Reports, Case Reports, Letters to the Editor, Commentaries, and Brief Reports.